Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Normal

<< Previous

Bullboard Posts

Next >>

Comment by Nicksonsnowboaron Dec 14, 2021 1:07pm

241 Views

Post# 34229568

RE:RE:RE:Normal

Well got to it's yearly low which was l expected. Looking to see it break 2 hopefully hit 1.50cdn. By years end. Should not be to hard as it seems to be taking 5 % plus per drop and with tax loss selling it should get there or lower State side around a $1

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading